Clinical trial

Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries

NCT01480791

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Aliskiren vs. hydrochlorothiazide Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Hydrochlorothiazide Normalized identity: hydrochlorothiazideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2012-01-01

PhasePHASE2

Conditions

Hypertensionunresolved

Diabetesverified · MONDO: diabetes mellitus

Interventions

Aliskiren vs. hydrochlorothiazideDRUG

HydrochlorothiazideDRUG · verified · RxNorm: hydrochlorothiazide

Sponsors & collaborators

Sir Mortimer B. Davis - Jewish General Hospitallead sponsor

Novartis Pharmaceuticalscollaborator

Mapped research locations

MontrealQuebec, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01480791 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.